Asthma prevalence management in pregnancy

Asthma prevalence management in pregnancy

Asthma is among the commonest chronic diseases during young adulthood, which determines a high prevalence of the disease in fertile and pregnant women. Asthmatic women behave in a very heterogeneous manner during pregnancy, with some of them experiencing an improvement of their health status, whereas others develop more severe asthma symptoms. In any case, asthma management during pregnancy is challenging for several reasons. Lung function tests like spirometry are sometimes difficult to perform or not recommended during pregnancy. This limitation makes difficult to assess for asthma control and to decide for the best therapeutic strategy. Nevertheless, poor asthma control during pregnancy poses an increased risk for bad outcomes in both the mother and the newborn. On the other hand, most medications used to treat asthma (including those administered through the inhaled route) are to some extent transported through the placenta and can be found in the fetus’ bloodsteam. This phenomenon raises many concerns especially considering that the new biologicals approved for severe asthma are all administered through systemic routes. Although the use of drugs able to pass through the placenta should be limited during pregnancy, not all of these medications are necessarilly harmful for the fetus. In summary, the management of asthma during pregnancy should keep a delicate balance between the need to control asthma and to prevent deleterious outcomes in both the mother and the fetus/newborn. In this task force we intend to conduct a systematic review of the literature about the prevalence and best management and therapeutic strategies for asthma during pregnancy. Similarly, we will identify research priorities on the topic.

Chair: Matteo Bonini
Secretary: Ibon Eguiluz Gracia